TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03970044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide 2 MG
Description: Glucagon-like peptide-1 receptor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide 2 MG
Description: Glucagon-like peptide-1 receptor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 MG
Description: sodium-glucose co-transporter 2 (SGLT2) inhibitor
Study: NCT02292212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViE-21
Description: The subjects will be undergone three times KUF measurement sessions and three times blood sampling sessions during study period.
Study: NCT00074958

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fabrazyme (agalsidase beta)
Description: 1 mg/kg every 2 weeks
Study: NCT00854100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant + cariprazine (0.1-0.3 mg/day)
Description: Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (0.1-0.3 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
Study: NCT04582838

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulse oximeter
Description: In both groups, pulse oximeters provide continuous monitoring of oxygen saturation (SpO2).~Also, SpO2 curve can be recorded for off-line analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulse oximeter
Description: In both groups, pulse oximeters provide continuous monitoring of oxygen saturation (SpO2).~Also, SpO2 curve can be recorded for off-line analysis.
Study: NCT00854100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant + cariprazine (1-2 mg/d)
Description: Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (1-2 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
Study: NCT03607032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respin Pad
Description: RespinPad slid into the back of the patient sitting at 45° in the armchair or bed.
Study: NCT04582838

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: ECG signal is used to monitor respiratory rate (RR).
Study: NCT03970044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: sodium-glucose co-transporter 2 (SGLT2) inhibitor
Study: NCT04503187

Intervention type: BEHAVIORAL
Intervention: Visuomotor leg reaching task
Description: Similar to a hand reaching task in which participants were asked to reach to a tea-cup, in a visuomotor leg reaching task, participants will be seated and given real-time visual feedback about their leg movements via a cursor display on a computer screen. The task is to control a foot mouse/marker attached to the foot and move the cursor from a start location to the target displayed on a wall screen. Three different targets, equidistant from the start location at top, top-left, and top-right screen positions, will be used for leg reaching. In each trial, one of three targets will be randomly presented and subjects will be instructed to make forward, or rightward, or leftward foot reaches to guide the cursor to one of the targets. Throughout the entire experiment, subjects are blocked from viewing leg movements by a cardboard.

Intervention type: BEHAVIORAL
Intervention: Visuomotor leg reaching task
Description: Similar to a hand reaching task in which participants were asked to reach to a tea-cup, in a visuomotor leg reaching task, participants will be seated and given real-time visual feedback about their leg movements via a cursor display on a computer screen. The task is to control a foot mouse/marker attached to the foot and move the cursor from a start location to the target displayed on a wall screen. Three different targets, equidistant from the start location at top, top-left, and top-right screen positions, will be used for leg reaching. In each trial, one of three targets will be randomly presented and subjects will be instructed to make forward, or rightward, or leftward foot reaches to guide the cursor to one of the targets. Throughout the entire experiment, subjects are blocked from viewing leg movements by a cardboard.

Intervention type: BEHAVIORAL
Intervention: Visuomotor leg reaching task
Description: Similar to a hand reaching task in which participants were asked to reach to a tea-cup, in a visuomotor leg reaching task, participants will be seated and given real-time visual feedback about their leg movements via a cursor display on a computer screen. The task is to control a foot mouse/marker attached to the foot and move the cursor from a start location to the target displayed on a wall screen. Three different targets, equidistant from the start location at top, top-left, and top-right screen positions, will be used for leg reaching. In each trial, one of three targets will be randomly presented and subjects will be instructed to make forward, or rightward, or leftward foot reaches to guide the cursor to one of the targets. Throughout the entire experiment, subjects are blocked from viewing leg movements by a cardboard.
Study: NCT01901796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy- an effective, non-pharmacological treatment for depression and anxiety.
Study: NCT02270996

Intervention type: OTHER
Intervention: Antimicrobial Stewardship Program
Description: Twice weekly meeting with Infectious Disease and Pediatric Surgery team members to audit antibiotics prescribed and suggest role for discontinuation.
Study: NCT03470181

Intervention type: DIETARY_SUPPLEMENT
Intervention: Ensure
Description: Participants will perform a Nutrient Drink Test. This consists of drinking 125mL of liquid Ensure four times, at five-minute intervals.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Ensure
Description: Participants will perform a Nutrient Drink Test. This consists of drinking 125mL of liquid Ensure four times, at five-minute intervals.
Study: NCT02575209

Intervention type: OTHER
Intervention: GENDER

Intervention type: OTHER
Intervention: GENDER
Study: NCT00407381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and pro re nata (PRN) with dosing criteria.
Study: NCT03607032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual treatment
Description: medical aerosol session followed by aspiration or not, as required

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual treatment
Description: medical aerosol session followed by aspiration or not, as required
Study: NCT00407381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and pro re nata (PRN) with dosing criteria.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser photocoagulation
Description: Laser photocoagulation in either focal or grid pattern as determined by investigator.
Study: NCT01959165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7183 low dose
Description: MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7183 medium dose
Description: MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7183 high dose
Description: MEDI7183 will be administered by SC on Day 1, and placebo for MEDI7183 at Week 2, 4, and 8

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo will be administered by SC on Day 1, Week 2,4, and 8
Study: NCT02381379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon-α-2a
Description: Subcutaneous peginterferon-α-2a (PEGASYS®) starting at 180µg weekly for one year.
Study: NCT01709331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Description: Corifollitropin alfa 150 μg by SC injection, once every 2 weeks for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: hCG 1500 or 3000 IU by SC injection twice a week; administered alone for 16 weeks (pre-treatment phase) and then in combination with corifollitropin alfa for 52 weeks (combined treatment phase)
Study: NCT03688217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Philani Intervention Model+MOVIE (PIM+M)
Description: The PIM+M intervention will involve the integration of the mobile video intervention into the standard perinatal counseling program offered by the intervention mentor-mothers. MOVIE intervention videos are narrated in English and isiXhosa, the languages spoken most widely among the study participants. Teaching videos are short (2-5 min.) and use simple language, avoiding medical jargon. The modularity of the videos facilitates delivery in any order and thus, they can be deployed at the discretion of each skilled mentor-mother, such that the health messages delivered are aligned with the individual needs of each participant at each perinatal stage. All videos will be administered at least once to each participant in the intervention group during the study period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Philani Intervention Model (PIM)
Description: The Philani Intervention Model (PIM) describes a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others.
Study: NCT00407381

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Description: Laser photocoagulation in either focal or grid pattern as determined by investigator.
Study: NCT00788905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allient System
Description: The Allient System uses a different type of blood pump and a lower volume of dialysate.
Study: NCT00588861

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Answer® hip stem
Description: Total hip replacement using Palacos® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Answer® hip stem
Description: Total hip replacement using Palacos® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Answer® hip stem
Description: Total hip replacement using Simplex® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Answer® hip stem
Description: Total hip replacement using Simplex® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
Study: NCT04314791

Intervention type: DEVICE
Intervention: Ultrasound evaluation, with grayscale and color Doppler imaging
Description: In pregnant women with previous CS and anterior low-lying or placenta previa, the following three sonographic criteria were assessed: (i) the smallest myometrial thickness in the sagittal plane; (ii) presence of placental lacunae and its grade from 0-3; (iii) bridging vessels using color Doppler. The PAI score (up to 9) was calculated for every patient as described by Rac et al.2015.
Study: NCT01578824

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine Challenge Test
Description: Evaluation of airway hyperreactivity as assessed by doubling dose of methacholine with determination of PC20
Study: NCT03018249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterectomy
Description: Undergo hysterectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Description: Undergo hysterectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00874926

Intervention type: BIOLOGICAL
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Haemophilia A patients
Study: NCT00514748

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DIEP
Description: flap survival, operation time, flap complications, donor site morbidity.
Study: NCT03018249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medroxyprogesterone Acetate
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone Acetate
Description: Given IM
Study: NCT00514748

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interconnected DIEP
Description: flap survival, operation time, flap complications, donor site morbidity.
Study: NCT01368562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Description: Methylnaltrexone will be administered as per the dose and schedule specified in the arm.
Study: NCT04415242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: positioning
Description: different positioning prior surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: positioning
Description: different positioning prior surgery
Study: NCT02631382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wet cupping
Description: In double cupping (traditional technique): Cupping (suction) then scarification then cupping (suction).~In single cupping (Asian): puncture using auto lancet then cupping (suction). In both techniques 4 out of 6 acupoints (BL23, BL24, BL25 bilateral) will be selected.
Study: NCT04351074

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIFT
Description: ligation of the intersphincteric fistula track

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fistulectomy
Description: excision of the fistulous track with its internal and external orifices
Study: NCT01538251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propionyl-L-Carnitine
Description: Modified release tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
Study: NCT03215563

Intervention type: RADIATION
Intervention: 18F PET-MRI
Description: 18F-fluoride Hybrid PET-MRI

Intervention type: RADIATION
Intervention: 18F PET-MRI
Description: 18F-fluoride Hybrid PET-MRI
Study: NCT01538251

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
Study: NCT00862797

Intervention type: OTHER
Intervention: pressure measurement during swallowing
Description: measurement of endotracheal tube cuff pressure during swallowing while recovering from anaesthesia
Study: NCT03215563

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Doppler
Description: Microembolic Signals detection
Study: NCT02012244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl-based analgesia
Description: fentanyl based patient-controlled analgesia + additional pethidine for postoperative 48 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local anesthetic wound infiltration-based anlagesia
Description: continuous wound inflitration with ropivacaine + tramadol patient-controlled analgesia + additional ketorolac or propacetamol for postoperative 48 hour
Study: NCT01051570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC = 5 by Calvert's formula, day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD 001
Description: 5 mg orally starting on Day 2 then continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 5 mg orally twice a day starting on Day 1 then continuous
Study: NCT01857921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin 20mg/day for 12 months after randomization
Description: Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:~1. Test group:~   * Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization~2. Control group:~   * Pravastatin 20mg daily for 12 months after randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg and trimetazidine MR 70 mg/day for 12 months after randomization
Description: Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:~1. Test group:~   * Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization~2. Control group:~   * Pravastatin 20mg daily for 12 months after randomization
Study: NCT03047525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced Killer Cells
Description: Concurrent of chemotherapy plus 4 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment and 4 cycles of Cytokine-induced Killer Cells(CIK) treatment
Study: NCT00777179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Tablet, oral, daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01051570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Samples will be collected from archival tissue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Samples will be collected Cycle 1, day 1, 2 \& 8 and Cycle 2, Day 1 \& 2
Study: NCT04622657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dubousset functional test
Description: Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
Study: NCT02152566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal High flow therapy device
Description: Nasal high flow therapy via nasal cannula.
Study: NCT04348162

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa flavanols and berries anthocyanins
Description: Effect of cocoa flavanols and berries anthocyanins on cardiovascular and cognitive health

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa flavanols and berries anthocyanins
Description: Effect of cocoa flavanols and berries anthocyanins on cardiovascular and cognitive health

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa flavanols and berries anthocyanins
Description: Effect of cocoa flavanols and berries anthocyanins on cardiovascular and cognitive health
Study: NCT05279391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 6-8 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 6-8 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 6-8 mg once daily
Study: NCT03566329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate
Description: Magnesium sulphate 50 mg/kg over 10 minutes loading followed by 15mg/kg/hr infusion. .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: lidocaine hydrochloride 1.5mg/kg loading followed by 2mg/kg/hr infusion
Study: NCT05279391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 6-8 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low molecular weight heparin
Description: Therapeutic doses of LMWH (e.g. Tinzaparin 175IU/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low molecular weight heparin
Description: Therapeutic doses of LMWH (e.g. Tinzaparin 175IU/kg)
Study: NCT03566329

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline infusion with the same rate of infusion as the study drugs
Study: NCT03799510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm14
Description: Three 0.5 mL intra-muscular injections of the vaccine solution (50μg Sm14) will be administered on D0, W4, W8 (D = day, W = week).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm14
Description: Three 0.5 mL intra-muscular injections of the vaccine solution (50μg Sm14) will be administered on D0, W4, W8 (D = day, W = week).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLA-SE solution
Description: The lot concentration 10μg/mL for injection of 2.5μg GLA-SE/injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLA-SE solution
Description: The lot concentration 10μg/mL for injection of 2.5μg GLA-SE/injection.
Study: NCT03692416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Infants and children with vasculitis attending AssiutU, aged \> 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests \& Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Ibuprofen for ANCA, C3, C4 \&C5a levels done, measured By ELISA technique.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Infants and children with vasculitis attending AssiutU, aged \> 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests \& Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Steroids for ANCA, C3, C4 \&C5a levels done, measured By ELISA technique.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Infants and children with vasculitis attending AssiutU, aged \> 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests \& Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Methotrexate for ANCA, C3, C4 \&C5a levels done, measured By ELISA technique.
Study: NCT01588275

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Description: Proper CPAP-pressure will be set for each patient separately.
Study: NCT01636843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0109-0012
Description: Administered subcutaneously (s.c., under the skin), once weekly.